Return on Tangible Equity: The amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity. Calculated as: Income from Continuing Operations / Tangible Shareholders Equity
Propanc Biopharma Inc (PPCB) had Return on Tangible Equity of -423.72% for the most recently reported fiscal year, ending 2025-06-30.
| Income Statement Financials | |
-- |
|
$-58.92M |
|
-- |
|
-- |
|
$57.28M |
|
$-57.28M |
|
$-1.65M |
|
$-58.92M |
|
$-58.92M |
|
$-58.92M |
|
$-58.92M |
|
$-58.92M |
|
$-58.92M |
|
$-57.28M |
|
$-57.28M |
|
0.16M |
|
0.16M |
|
$-371.25 |
|
$-371.25 |
|
| Balance Sheet Financials | |
$8.35M |
|
-- |
|
$11.28M |
|
$19.63M |
|
$5.58M |
|
$0.11M |
|
$0.15M |
|
$5.73M |
|
$13.91M |
|
$13.91M |
|
$13.91M |
|
0.46M |
|
| Cash Flow Statement Financials | |
$-0.41M |
|
-- |
|
$0.49M |
|
$0.02M |
|
$0.01M |
|
$-0.01M |
|
-- |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
1.50 |
|
-- |
|
-- |
|
0.01 |
|
0.12 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-0.41M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-423.72% |
|
|
Return on Tangible Equity |
-423.72% |
-300.14% |
|
-420.53% |
|
$29.94 |
|
$-2.55 |
|
$-2.55 |
|